

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 August 2003 (14.08.2003)

PCT

(10) International Publication Number
WO 03/066209 A1

(51) International Patent Classification⁷: B01J 13/18,
13/20, A61K 7/00

(21) International Application Number: PCT/EP03/01071

(22) International Filing Date: 3 February 2003 (03.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0202853.8 7 February 2002 (07.02.2002) GB

(71) Applicant (for all designated States except US): DOW CORNING CORPORATION [US/US]; Midland, MI 48611 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MARTEAUX, Leon [BE/BE]; Clos du Bergoje 35, B-1160 Brussels (BE). GIR-BOUX, Anne-Lise [BE/BE]; Avenue Beatrice de Cusance 44, Bte 3, B-1420 Braine l'Alleud (BE). LABROSSE, Arnaud [FR/BE]; Avenue de Scailmont 40, B-7170 Manage (BE). POLSTER-RENARD, Catherine [BE/BE]; Rue de la Prairie 55, B-7830 Hellebecq (BE). VAN REETH, Isabelle [BE/BE]; 8, rue Ecole des Filles, B-1315 Incourt (BE).

(74) Agents: DAVIES, Peter, V. et al.; Dow Corning Limited, Cardiff Road, Barry CF63 2YL (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW. ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW. ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/066209 A1

(54) Title: ENCAPSULATION PROCESS AND ENCAPSULATED COMPOSITIONS

(57) Abstract: A lipophilic cosmetic, chemical, biological or pharmaceutical active material composition encapsulated within a shell of the emulsion polymerisation product of a tetraalkoxysilane. A water reactive silicon compound comprising tetraalkoxysilane is added to an aqueous emulsion of the active material composition having a positive zeta-potential, whereby the tetraalkoxysilane condenses and polymerises at the interface of the emulsified droplets of the lipophilic active material composition to form microcapsules having a core of the active material composition surrounded by a shell of silicon-based network polymer.

ENCAPSULATION PROCESS AND ENCAPSULATED COMPOSITIONSFIELD OF THE INVENTION

5 [0001] This invention relates to a process for encapsulating materials such as cosmetic, chemical or pharmaceutical active material compositions and to the encapsulated compositions which can be formed thereby. It is of particular use in encapsulating sunscreen active materials and can also be used for other cosmetic actives, such as perfumes, for other chemical materials and for pharmaceutical active materials.

10 [0002] In some personal care products, the cosmetic active material may be present in high amounts. For example, a SPF (sun protection factor) 15 sun cream or lotion may contain over 5% by weight sunscreen active materials (UV blockers). Moreover, some cosmetic active materials, including UV blockers, can be skin irritants or should not be absorbed through the skin. There is a need for products which prevent or inhibit skin contact by such a cosmetic active material.

BACKGROUND TO THE INVENTION

20 [0003] JP-A-2-2867 describes sunscreen benzophenone derivatives encapsulated in fine spherical silica particles. The sunscreen is dissolved in aqueous alkali metal silicate solution and is emulsified in an organic non-solvent to form a water-in-oil emulsion. The emulsion is acidified to form a water-insoluble precipitate of sunscreen encapsulated in silica. The process of JP-A-2-2867 is suitable for hydrophilic sunscreen active materials, but most sunscreen active materials are lipophilic.

25 [0004] WO-A-98/31333 describes sunscreen-doped sol-gel materials and a method for their preparation comprising condensation polymerising a metal or semi-metal alkoxide or ester in the presence of at least one sunscreen ingredient, resulting in the entrapment of the sunscreen ingredients within the formed sol-gel matrix.

[0005] US-A-6303149 describes a process for preparing sol-gel microcapsules loaded with functional molecules by emulsifying sol-gel precursors and the functional molecules in an aqueous solution, and mixing the emulsion with an acidic, neutral or basic aqueous solution to obtain a suspension of microcapsules. US-A-6238650 describes a sunscreen composition comprising at least one sunscreen active ingredient and a cosmetically acceptable vehicle, wherein said sunscreen active ingredient is in the form of sol-gel microcapsules containing at least one sunscreen compound. The sol-gel microcapsules are prepared by the method disclosed in US-A-6303149.

[0006] EP-A-281034 describes a perfume encapsulated and/or clathrated in a matrix of inorganic polymer prepared from a metal alkoxide such as tetraethyl orthosilicate (TEOS). An aqueous dispersion or solution of perfume and TEOS is treated with an acid catalyst to cause hydrolysis, then with a base catalyst to cause polymerisation to a gel.

[0007] EP-A-941761 describes a process for preparing microcapsules with an organopolysiloxane shell and a core material, in which the shell is formed in situ by hydrolysis and polycondensation of an organosilane and/or a condensation product thereof having at most 4 silicon atoms. JP-51-78995-A describes dispersing a silyl-treated pigment with TEOS in acetone and adding to ammoniacal aqueous ethanol with stirring to form a micropowder of particles having a pigment core.

[0008] EP-A-934773 describes microcapsules whose capsule wall comprises organopolysiloxane synthesised by polycondensing a compound of the formula $R_nSi(OH)_mY_{(4-m-n)}$ where m=1-4; n=0-3; R represents an organic group with a C atom directly bonded to a Si atom; and Y is an alkoxy group, H or a siloxy group.

[0009] WO-A-00/71084 describes preparing a sunscreen composition with improved photostability that contains at least two sunscreen actives which are photo-unstable when formulated together by microencapsulating at least one of the actives and adding other components of the sunscreen composition.

[0010] WO-A-01/80823 describes a therapeutic or cosmetic composition comprising microcapsules of diameter 0.1-100 μ having a core-shell structure. The core includes at least one active. The shell comprises an inorganic polymer obtained by a sol-gel process, and releases the active after topical application.

5

[0011] There is a need for cosmetic active materials, particularly sunscreens, in a form in which the active material is inhibited from skin contact but which contains a high proportion of the active material and can readily be incorporated into a cosmetic preparation such as a lotion or cream.

10

SUMMARY OF THE INVENTION

[0012] According to one aspect of the present invention, a process for encapsulating a lipophilic cosmetic, chemical, biological or pharmaceutical active material composition is characterised in that a water reactive silicon compound comprising tetraalkoxysilane is added to an aqueous emulsion of the active material composition having a positive zeta-potential, whereby the tetraalkoxysilane condenses and polymerises at the interface of the droplets in the emulsion to form microcapsules having a core of the active material composition surrounded by a shell of silicon-based network polymer. We use the term 'emulsion' to mean a liquid in liquid dispersion and 'suspension' to mean a solid in liquid dispersion.

[0013] The invention also includes an encapsulated cosmetic, chemical, biological or pharmaceutical active material composition, characterised in that the encapsulated composition comprises microcapsules of a lipophilic cosmetic, chemical, biological or pharmaceutical active material composition encapsulated within a shell of the emulsion polymerisation product of a tetraalkoxysilane.

[0014] The invention also includes a process for the preparation of an encapsulated lipophilic cosmetic, chemical, biological or pharmaceutical active material composition, characterised in that an aqueous emulsion of the active material composition is mixed with a water-reactive silicon compound, thereby forming a suspension of microcapsules having a

core of the active material composition and a shell of silicon-based network polymer, and the microcapsules are post-treated with a water-reactive metal alkoxy or acyloxy compound.

DETAILED DESCRIPTION OF THE INVENTION

5

[0015] The tetraalkoxysilane such as tetraethoxysilane (TEOS) can be used in monomeric form or as a liquid partial condensate. The tetraalkoxysilane can be used in conjunction with one or more other water-reactive silicon compound having at least two, preferably at least 3, Si-OH groups or hydrolysable groups bonded to silicon, for example an alkyltrialkoxysilane such as methyltrimethoxysilane or a liquid condensate of an alkyltrialkoxysilane. Hydrolysable groups can for example be alkoxy or acyloxy groups bonded to silicon. The water reactive silicon compound can for example comprise 75-100% by weight tetraalkoxysilane and 0-25% trialkoxysilane. The alkyl and alkoxy groups in the tetraalkoxysilanes or other silanes preferably contain 1 to 4 carbon atoms, most preferably 1 or 2 carbon atoms. The tetraalkoxysilane, and other water-reactive silicon compound if used, hydrolyses and condenses to form a network polymer, that is a 3-dimensional network of silicon-based material, around the emulsified droplets of the lipophilic active material composition. The water-reactive silicon compound preferably consists of at least 75%, and most preferably 90-100% tetraalkoxysilane. We have found that a tetraalkoxysilane is the most effective silicon compound for forming impermeable microcapsules, forming a 3-dimensional network consisting substantially of $\text{SiO}_{4/2}$ units.

10

15

20

[0016] The lipophilic cosmetic, chemical, biological or pharmaceutical active material composition is a liquid at the time it is emulsified and usually is liquid at ambient

25

temperature. It can be an undiluted liquid active material or can be a solution of an active material in a lipophilic solvent, preferably a non-volatile solvent, or a water-in-oil or oil-in-water-in-oil emulsion, or a lipophilic suspension. Solid active materials can be melted before being emulsified if their melting temperature is significantly below 100°C.

30

[0017] The active material can for example be a sunscreen. Sunscreen active compounds which are used in the invention can for example be UV-B blockers such as 2-ethylhexyl methoxycinnamate, generally known as octyl methoxycinnamate or UV-A

blockers such as butylmethoxydibenzoylmethane known as avobenzone. Mixtures of sunscreen compounds can be used, for example a mixture of octyl methoxycinnamate with octocrylene, although octyl methoxycinnamate and avobenzone are known to be photolytically unstable when mixed in high concentrations and should preferably not be encapsulated together. Octyl methoxycinnamate is liquid and can be used undiluted. Butylmethoxydibenzoylmethane is a solid which can be dissolved in an inert lipophilic liquid.

5 [0018] Sunscreen active compounds can perform their function of screening out harmful UV radiation while they are encapsulated. The silicon-based polymer forming the shell of the microcapsules does not absorb UV and has no negative impact on the sunscreen efficiency, and may potentially improve the protection against photodegradation. An encapsulated sunscreen according to the invention preferably has a substantially impermeable silicon-based polymer shell.

10 15 [0019] Another type of cosmetic active material which can be encapsulated is a perfume. In this case the active material composition which is mixed with the water reactive silicon compound may comprise a diluent as well as the active perfume or fragrance compounds. The diluent is preferably odourless and non-volatile and can for example be a non-reactive polydiorganosiloxane or a nonvolatile liquid hydrocarbon or ester. When 20 encapsulating perfume, a permanent shell is not required. The shell may be breakable, for example brittle, so that the microcapsules are broken under the application of shear, releasing the perfume. Larger particles of diameter at least 10 μ m, for example 50 μ m or above, are more readily breakable than smaller particles.

25 30 [0020] Other examples of active materials which may be encapsulated are UV absorbers for use in coatings, paints, plastics materials, sealants or textile finishes to improve weatherability and resist fading (such UV absorber compositions are preferably encapsulated in an impermeable silicon-based polymer shell), pharmaceuticals or sensitive chemical materials. Pharmaceuticals and related health products such as vitamins can be encapsulated in a silicon-based polymer shell which is broken down in the body after ingestion of the pharmaceutical. Biological (including biochemical) materials such as proteins, enzymes and cells can similarly be encapsulated. Radioactive material can be encapsulated for cancer

treatment. Water insoluble liquid chemical materials can be protected, for example during storage or transport. Encapsulation can alternatively be used to modify the surface properties, optical properties or feel and taste of any core material.

5 [0021] The lipophilic active material composition is emulsified in an aqueous medium preferably with the aid of a surfactant. The particle size of the emulsion of active material composition is generally in the range 0.01 to 500, preferably 0.1 to 50 micrometres. The emulsion can alternatively be a microemulsion of particle size 10-150 nm. The surfactant is most preferably a cationic or amphoteric surfactant, which readily forms an emulsion of positive zeta-potential. We have found that a positive zeta-potential promotes condensation and polymerisation of the tetraalkoxysilane at the interface of the emulsified droplets of the lipophilic active material composition, leading to more impervious microcapsules. Nonionic surfactants can be used; for example the cationic or amphoteric surfactant can be mixed with up to an equal weight of nonionic surfactant.

15 [0022] The concentration of surfactant in the aqueous emulsion of lipophilic active material can be between 0.01 and 10% by weight, but is preferably at least 0.02% and below 2%, most preferably 0.05 to 1.5% by weight of the emulsion, particularly 0.2-1.0%. We have found in general that the use of low levels of surfactant during emulsification of the lipophilic active material and reaction with the alkoxy silane leads to microcapsules which are more resistant to diffusion or leaching of the lipophilic active material from the microcapsules. Subsequent addition of surfactant to the suspension of microcapsules has less or no effect on diffusion or leaching of the lipophilic active material from the microcapsules.

25 [0023] The weight ratio of oil phase to aqueous phase in the emulsion can generally be between 40:1 and 1:50, although the higher proportions of aqueous phase are economically disadvantageous particularly when forming an emulsion of microcapsules. Usually the weight ratio of oil phase to aqueous phase is between 2:1 and 1:3. If the active material composition is highly viscous, a phase inversion process can be used in which the oil phase is 30 mixed with surfactant and a small amount of water, for example 2.5 to 10% by weight based on the oil phase, forming a water-in-oil emulsion which inverts to an oil-in-water emulsion as

it is sheared. Further water can then be added to dilute the emulsion to the required concentration.

[0024] Examples of cationic surfactants include quaternary ammonium hydroxides such as octyl trimethyl ammonium hydroxide, dodecyl trimethyl ammonium hydroxide, hexadecyl trimethyl ammonium hydroxide, octyl dimethyl benzyl ammonium hydroxide, decyl dimethyl benzyl ammonium hydroxide, didodecyl dimethyl ammonium hydroxide, dioctadecyl dimethyl ammonium hydroxide, tallow trimethyl ammonium hydroxide and coco trimethyl ammonium hydroxide as well as corresponding salts of these materials, fatty amines and fatty acid amides and their derivatives, basic pyridinium compounds, quaternary ammonium bases of benzimidazolines and polypropanolpolyethanol amines. Cationic emulsions of microcapsules have increased deposition of the microcapsules from the emulsion and increased substantivity on both hair and skin.

[0025] Examples of suitable amphoteric surfactants include cocamidopropyl betaine, cocamidopropyl hydroxysulfate, cocobetaine, sodium cocoamidoacetate, cocodimethyl betaine, N-coco-3-aminobutyric acid and imidazolinium carboxyl compounds.

[0026] The above surfactants may be used individually or in combination.

[0027] Examples of non-ionic surfactants include polyoxyalkylene alkyl ethers such as polyethylene glycol long chain (12-14C) alkyl ether, polyoxyalkylene sorbitan ethers, polyoxyalkylene alkoxylate esters, polyoxyalkylene alkylphenol ethers, ethylene glycol propylene glycol copolymers, polyvinyl alcohol and alkylpolysaccharides, for example materials of the structure $R^1-O-(R^2O)_m-(G)_n$ wherein R^1 represents a linear or branched alkyl group, a linear or branched alkenyl group or an alkylphenyl group, R^2 represent an alkylene group, G represents a reduced sugar, m denotes 0 or a positive integer and n represent a positive integer as described in US Patent 5,035,832.

[0028] The continuous phase of the emulsion can be a mixture of water with a water-miscible organic solvent such as an alcohol or lactam provided that the continuous phase is not miscible with the lipophilic active material. The particle size of the emulsion of

lipophilic active material can be reduced before addition of the water-reactive silicon compound, for example in an apparatus applying increased shear such as a homogeniser or microfluidiser, or a sonolator (ultrasonic mixer), producing an emulsion of microcapsules of particle size 100-1000 nm, most preferably between 200 nm and 500 nm. The emulsion can 5 alternatively be prepared by phase inversion.

[0029] The particle size of the microcapsules produced generally corresponds to the particle size of the starting emulsion and can for example be in the range 0.01-500 μm , most preferably 200 nm to 10 μm . For some uses, microcapsules of particle size 1-500 μm , 10 particularly up to 50 or 100 μm , may be preferred. If an emulsion of this particle size is required, the aqueous phase of the emulsion preferably contains a thickener, for example polyvinylpyrrolidone, polyvinyl alcohol, bentonite clay, a cellulose derivative, particularly a cellulose ether such as sodium carboxymethylcellulose, a lightly crosslinked acrylic polymer, modified starch, an alginic or xanthan gum, to inhibit settling of the microcapsules from the 15 emulsion during formation or subsequently. The thickener is added to the emulsion before addition of the tetraalkoxysilane. We have found that addition of polyvinylpyrrolidone to the emulsion before addition of the tetraalkoxysilane promotes formation of microcapsules more resistant to diffusion of the lipophilic material from the microcapsules for most particle sizes of the microcapsules.

[0030] The tetraalkoxysilane, and other water reactive silicon compound if used, can be added to the emulsion of active material composition as an undiluted liquid or as a solution in an organic solvent or in an emulsion form. The tetraalkoxysilane and the emulsion are generally mixed under shear during addition and subsequently during 25 condensation to form the silicon-based polymer shell on the surface of the emulsified droplets. Mixing can for example be by stirring, but it is preferred that the emulsion and the tetraalkoxysilane are subjected to high shear, for example in a mixer of the rotor and stator type such as a Silberson (trade mark) mixer, either during addition of the tetraalkoxysilane or after addition of the tetraalkoxysilane and before formation of microcapsules is complete. 30 High shear mixing immediately after addition of the tetraalkoxysilane is preferred. This leads to microcapsules of reduced particle size and appears to promote polymerisation of substantially all the tetraalkoxysilane at the interface of the emulsion droplets.

[0031] The condensation reaction can be conducted at acidic, neutral or basic pH. The condensation reaction is generally carried out at ambient temperature and pressure, but can be carried out at increased temperature, for example up to 95°C, and increased or 5 decreased pressure, for example under vacuum to strip the volatile alcohol produced during the condensation reaction. The weight ratio of active material composition to water reactive silicon compound is preferably at least 0.5:1 and in many cases may be at least 1.5:1, for example 2:1 to 9:1. Smaller microcapsules, for example those formed from a microemulsion, generally have a lower ratio of active material composition to water reactive silicon 10 compound.

[0032] A catalyst for hydrolysis and/or condensation of the water reactive silicon compound to form the silicon-based polymer may be used. The catalyst is preferably an oil soluble organic metal compound, for example an organic tin compound, particularly an 15 organotin compound such as a diorganotin diester, for example dimethyl tin di(neodecanoate), dibutyl tin dilaurate or dibutyl tin diacetate, or alternatively a tin carboxylate such as stannous octoate, or an organic titanium compound such as tetrabutyl titanate. An organotin catalyst can for example be used at 0.05 to 2% by weight based on the water reactive silicon compound. An organotin catalyst has the advantage of effective 20 catalysis at neutral pH. A catalyst is most preferably mixed with the lipophilic cosmetic, chemical or pharmaceutical active material composition before it is emulsified, since this promotes condensation of the water reactive silicon compound at the surface of the emulsified lipophilic droplets. A catalyst can alternatively be added to the emulsion before the addition of the water-reactive silicon compound, or simultaneously with the water-reactive silicon 25 compound, or after the addition of the water-reactive silicon compound to harden and make more impervious the shell of silicon-based polymer which has been formed. Encapsulation can however be achieved without catalyst, and we have found in some cases that microcapsules formed with a low level of catalyst or no catalyst are more resistant to diffusion or leaching of the lipophilic active material from the microcapsules. The catalyst, 30 when used, can be added undiluted, or as a solution in an organic solvent such as a hydrocarbon, alcohol or ketone, or as a multiphasic system such as an emulsion or suspension.

[0033] The product of hydrolysis and condensation of the water reactive silicon compound is an aqueous suspension of microcapsules. The aqueous continuous phase can contain water miscible organic solvent; for example it usually contains an alcohol such as ethanol generated by hydrolysis of Si-bonded alkoxy groups. It may be advantageous to use 5 the suspension of microcapsules in a water based preparation, for example a cosmetic, chemical or pharmaceutical product without separating the microcapsules from the suspension. In particular, a suspension of encapsulated sunscreen can be incorporated direct into a sunscreen lotion or cream or can even be used itself as a sunscreen lotion. The suspension of encapsulated sunscreen can be used in conjunction with other sunscreens, if 10 desired. For example, an encapsulated UV-B absorber such as octyl methoxycinnamate can be formulated with a UV-A absorber such as avobenzone and optionally with other sunscreens. The UV-A absorber in such a formulation can be free or encapsulated.

[0034] For many uses it may be preferred to recover the microcapsules from 15 suspension, for example for subsequent dispersion in a different medium. An encapsulated sunscreen can for example be dispersed in a water based cosmetic preparation, preferably in such a proportion that the content of sunscreen in the cosmetic preparation is 0.1 to 10% by weight. Alternatively the microcapsules can be redispersed in an organic solvent, optionally 20 with additives such as surfactant and/or polymer. Recovery of the microcapsules can be achieved by any known liquid removal technique, for example by spray drying, spray chilling, filtering, oven drying or lyophilisation.

[0035] Alternative uses of encapsulated sunscreens according to the invention are in 25 fabric treatment, for example the suspension of microcapsules or the separated microcapsules can be incorporated in a fabric softener to inhibit subsequent colour fading of the fabric, or in plastics compositions or coatings which are designed to be exposed to sunlight or UV light in use.

[0036] The encapsulated product can be post-treated with a water-reactive metal 30 alkoxy or acyloxy compound. The metal compound should be gradually hydrolysed in water rather than immediately reacting with water; compounds of Group IVB, IVA or VA of the Periodic Table are suitable such as compounds of silicon, titanium, zirconium or vanadium.

The water-reactive metal alkoxy or acyloxy compound can for example harden the shell of the microcapsules and/or make them more impermeable. The reactive metal alkoxy or acyloxy compound can for example be an alkoxy silane or acyloxy silane, particularly a trialkoxysilane such as methyl triethoxy silane or isobutyl triethoxy silane, or a silane having Si-H functionality such as tris(dimethylhydrogensilyloxy) n-octyl silane, or alternatively a titanium alkoxide (alkyl titanate).

[0037] The reactive metal alkoxy or acyloxy compound can have an organic functional group to promote adhesion to substrates, especially textile substrates, for example 10 3-methacryloxypropyl trimethoxy silane, 3-aminopropyl triethoxysilane, 3-aminopropyl trimethoxy silane, 3-glycidoxypipropyl trimethoxy silane and 3-(2-aminoethylamino)propyl trimethoxy silane. The microcapsules can be post-treated with a reactive metal alkoxy or acyloxy compounds, e.g. an alkoxy silane to change their physical and/or chemical properties, for example by making the capsule surface more hydrophobic or more hydrophilic. For 15 example, the microcapsule surface can be made more hydrophobic by reaction with a silane having a long chain alkyl group such as octyl triethoxy silane. As an alternative to chemical reaction the microcapsules can be coated with a material which alters their surface properties. The surface treatment can be carried out on the microcapsules in suspension or on the separated solid microcapsules.

[0038] The microcapsules according to the invention inhibit diffusion or leaching of 20 the lipophilic cosmetic, chemical, biological or pharmaceutical active material from the microcapsules. When encapsulating sunscreen, for example, it is preferred that the rate of diffusion or leaching is as low as possible. For other lipophilic active materials a controlled rate of release may be preferred, and this can be achieved by adjusting the level of surfactant, the level of tetraalkoxysilane and optionally of trialkoxysilane, the particle size and the level 25 of catalyst.

[0039] Microcapsules according to the invention containing cosmetic active material 30 compositions, including sunscreens, have good skin adhesion. The microcapsules minimise contact between the sunscreen and the skin, resulting in decreased penetration and consequently less potential irritation and allergy. The emulsion of microcapsules can have a

high concentration of sunscreen (high pay load) compared to an aqueous dispersion of sunscreen, increasing the ease of use of lipophilic sunscreens in surfactant based product and allowing the sunscreen preparation to have a very liquid product form, which may be sprayable. Encapsulation eliminates the greasy feel associated with lipophilic sunscreens, 5 increasing the acceptability and use in skin care products. The microcapsule does not affect the photostability of the encapsulated sunscreen. Exposure for 20 minutes to irradiation by a 19 mW/cm² UV A lamp and a 0.6 mW/cm² UV B lamp (equivalent to 1 hour sunshine as described in WO01/24762) gives less than 10% reduction in the sun protection factor of an encapsulated octyl methoxycinnamate composition. The silicon-based polymer forming the 10 shell of the microcapsules generally remains water insoluble even in the presence of surfactant, so that the encapsulated cosmetic active can be used in water based toiletry preparations including surfactant based products such as hair shampoo, conditioner or colourant, textile softener, detergent or shower gel.

15 [0040] The invention is illustrated by the following Examples in which parts and percentages are by weight:

EXAMPLES

20 Example 1

[0041] 41.33g octylmethoxycinnamate (OMC, a UV-B sunscreen oil) was emulsified in 53.1g water containing 1.64g Volpo L3 (Trade Mark) nonionic polyethylene glycol lauryl ether surfactant and 3.66g Arquad 16-29 (Trade Mark) cetyl trimethyl ammonium chloride 25 cationic surfactant. The coarse emulsion was passed twice through a "Rannie Mini Lab 8.30 H" homogeniser operating at 950 bars. 17.71g TEOS was added to the emulsion while stirring to form a coarse emulsion of microcapsules. Microcapsules of median diameter 372nm were produced in suspension. When the microcapsules were tested using a leaching procedure to extract non-encapsulated oil, the degree of encapsulation was 97%.

Example 2

[0042] Example 1 was repeated with the addition of 0.236g dimethyltin dineodecanoate catalyst just after the TEOS. Microcapsules of median diameter 372nm were produced with an encapsulation yield of 89%. The suspension of microcapsules had an OMC content of 35.1% and the separated microcapsules had an OMC content of 89%.

[0043] In vitro SPF (sun protection factor) measurements together with sensory evaluation have been conducted on the suspension of microcapsules in comparison to an emulsion containing the same level of OMC not encapsulated. The samples were applied to a substrate called " Mimson(R) and SPF measurements were made using a Labsphere UV-1000 SPF Analyser at 25°C. The results are reported in Table 1 below

Table 1

15

	In-vitro SPF
Emulsion with non encapsulated OMC	7.41
Encapsulated OMC of Example 2	24.4

[0044] Table 1 shows that the encapsulation does not have any negative impact on the sunscreen efficiency and could even have a positive impact.

20

[0045] Sensory evaluation by a triangular test method demonstrated a decrease of the greasy feel of the sunscreen.

25

[0046] The resistance of the encapsulated sunscreens of Examples 1 and 2 to leaching of OMC from the microcapsules was tested by an aggressive method in which the suspension of microcapsules was dispersed at 1% in a paraffinic solvent and the OMC content of the paraffin was measured by UV spectroscopy at different time intervals after dispersion. The concentration of OMC in the paraffin was found to increase in a linear manner with time (zero order delivery of OMC). In this test, 47% of the OMC was extracted from the microcapsules of Example 1 after 24 hours and 71% of the OMC was extracted from the

microcapsules of Example 2 after 24 hours. Without encapsulation, over 80% of the OMC is extracted from the emulsion of OMC in 4 hours. By comparison, when the Arquad 16-29 cationic surfactant was replaced by an anionic surfactant, substantially all the OMC was extracted from the capsules in 4 hours.

5

Example 3

[0047] Example 1 was repeated except that 0.236g dimethyltin dineodecanoate catalyst was mixed into the OMC before it was emulsified, and only 46.6g water was used.

10 Microcapsules of median diameter 329nm were produced with an encapsulation yield of 98%.

Example 4

[0048] 51.0g OMC was mixed with 19.0g avobenzone UV-A sunscreen oil and 15 0.400g dimethyltin dineodecanoate catalyst and emulsified in 90g water using 2.77g Laureth 3 and 6.20g Arquad 16-29. 30.0g TEOS was added and microcapsules were produced by the procedure described in Example 1. Microcapsules of median diameter 400nm were produced with a specific area of 17 m²/g.

20 Example 5

[0049] 0.2% xanthan gum was dispersed in 61.16% water at 60oC and mixed with 4% nonionic emulsifier and 2% glycerine. 10% cyclopentasiloxane was mixed with 4% capric/caprylic triglycerides and 0.5% preservative and heated to 60oC, then mixed with the 25 above aqueous dispersion. The resulting emulsion was allowed to cool to 35oC and 17.14% of the suspension of microcapsules produced in Example 2 was added to form an oil in water sunscreen cream containing 6% OMC.

[0050] In vitro SPF measurements were performed on the above cream in comparison 30 with a similar cream containing no microcapsules but containing 6% OMC mixed into the cyclopentasiloxane phase. The results are shown in Table 2.

Table 2

	In-vitro SPF
O/w cream with non encapsulated OMC	5.24
O/w cream with encapsulated OMC of Example 2	10.18

[0051] As can be seen from Table 2, the encapsulated OMC gives a higher SPF than 5 non-encapsulated OMC.

[0052] Sensory evaluation tests using paired comparison methods were conducted on the creams containing encapsulated and non encapsulated OMC. The results showed a positive impact of the encapsulated product on the speed of absorption of the cream.

10

Example 6

[0053] 17.0% of the suspension of microcapsules produced in Example 2 was diluted in 56.0% water containing 2.0% NaCl and then dispersed into 25.0% of a mixture of 15 cyclomethicone and dimethicone copolyol slowly under strong agitation. The dispersion was passed through a homogeniser to produce a water in oil sunscreen cream.

[0054] Pigments can be added to the formulation of Example 6 or the formulation of Example 5 to make a foundation product with sun protection.

20

Example 7

[0055] 10.0% lauryl ether sulfate anionic surfactant was mixed with 2.5% decyl polyglucoside and 5.0% cocamidopropyl betaine. 2.0% Laureth-4 nonionic surfactant was 25 added under strong agitation, followed by 7.5% of the encapsulated sunscreen suspension of Example 2, then 0.5% NaCl, citric acid and KOH to pH 6.5, preservatives and water to 100% to form a shower gel or shampoo which gives sun protection.

Example 8

[0056] 1.5% hydroxyethyl cellulose (HEC) was dispersed in 85.5% water and heated to 80 °C. 1.0 % cetearyl alcohol and 1.0 % of a mixture of polyethylene glycol (100) stearate and glyceryl Stearate were melted at 80 °C and the HEC dispersion was added under strong agitation. The resulting dispersion was allowed to cool down to 35 °C and 11.0% of the encapsulated sunscreen suspension of Example 2 was added, followed by preservative to from a rinse-off conditioner giving sun protection.

10 [0057] A leave-on conditioner with sun protection can be formed by simply diluting the encapsulated sunscreen suspension and adding preservative and perfume.

Examples 9 and 10

15 [0058] The process of Example 2 was repeated with the omission of the nonionic surfactant and the reduction of the amount of Arquad 16-29 cationic surfactant to 1.83g (Example 9) and 0.915g (Example 10).

Example 11

20 [0059] The process of Example 2 was repeated with the omission of the cationic surfactant.

Example 12

25 [0060] The process of Example 11 was repeated with the amount of Volpo L3 nonionic surfactant being halved to 0.82g.

Examples 13 and 14

[0061] The process of Example 1 was repeated with the omission of the nonionic surfactant and the reduction of the amount of Arquad 16-29 cationic surfactant to 0.915g (Example 13) or to 0.366g (Example 14).

[0062] The suspensions of microcapsules produced in Examples 9 to 13 were tested by the paraffinic solvent extraction method described above. The amount of OMC extracted after 24 hours is shown in Table 3 below.

10

Table 3

<u>Example No</u>	<u>% extracted</u>
<u>9</u>	<u>8</u>
<u>10</u>	<u>4</u>
<u>11</u>	<u>38</u>
<u>12</u>	<u>25</u>
<u>13</u>	<u>4</u>
<u>14</u>	<u>3</u>

[0063] The test results of the microcapsule suspensions of Example 9, 10, 13 and 14 correspond to negligible leaching of the OMC from the microcapsules in a normal sunscreen vehicle. For the suspension of Example 14, the test was continued to 120 hours at which time 21% of the OMC was extracted.

Example 15

20

[0064] Example 14 was repeated with an increase of the amount of TEOS added to 22.14g (25% increase). When the resulting suspension of microcapsules was tested by the paraffinic solvent extraction method described above, the amount of OMC extracted after 24 hours was 9% compared to 28% for the suspension of Example 14.

CLAIMS

1. A process for encapsulating a lipophilic cosmetic, chemical, biological or pharmaceutical active material composition, characterised in that a water reactive silicon compound comprising tetraalkoxysilane is added to an aqueous emulsion of the active material composition having a positive zeta-potential, whereby the tetraalkoxysilane condenses and polymerises at the interface of the emulsified droplets of the lipophilic active material composition to form microcapsules having a core of the active material composition surrounded by a shell of silicon-based network polymer.
2. A process according to Claim 1, characterised in that the active material composition is emulsified in an aqueous medium in the presence of a cationic surfactant to form the aqueous emulsion of positive zeta-potential.
3. A process according to Claim 1 or Claim 2, characterised in that the water reactive silicon compound comprises tetraethyl orthosilicate.
4. A process according to any of Claims 1 to 3, characterised in that the concentration of surfactant in the emulsion is 0.02 to 2.0% by weight of the emulsion.
5. A process according to any of Claims 1 to 4, characterised in that a catalyst for hydrolysis and/or condensation of the water reactive silicon compound is added to the emulsion before, during or after the addition of the water-reactive silicon compound.
6. A process according to Claim 5, characterised in that the catalyst is an organic tin compound.

7. A process according to any of Claims 1 to 6, characterised in that the emulsion is passed through a high shear mixer after addition of the tetraalkoxysilane and before formation of microcapsules is complete.
8. A process according to any of Claims 1 to 7, characterised in that polyvinylpyrrolidone is added to the emulsion before addition of the tetraalkoxysilane.
9. A process for the preparation of an encapsulated lipophilic cosmetic, chemical, biological or pharmaceutical active material composition, characterised in that an aqueous emulsion of the active material composition is mixed with a water-reactive silicon compound, thereby forming a suspension of microcapsules having a core of the active material composition and a shell of silicon-based network polymer, and the microcapsules are post-treated with a water-reactive metal alkoxy or acyloxy compound.
10. A process according to Claim 9 characterised in that the water-reactive metal compound is an alkoxy silane.
11. A process according to any of Claims 1 to 10, characterised in that the active material is a liquid sunscreen composition.
12. A process according to any of Claims 1 to 11, characterised in that the microcapsules are separated from suspension by a liquid removal technique.
13. A method of producing a water based preparation comprising a lipophilic cosmetic, chemical, biological or pharmaceutical active material, characterised in that a suspension of encapsulated lipophilic cosmetic, chemical, biological or pharmaceutical active material composition is prepared according to any of Claims 1 to 11 and is incorporated direct into the water based preparation without separation of the microcapsules from the suspension.

14. A method for the preparation of a water based cosmetic preparation containing an encapsulated sunscreen, characterised in that a water based cosmetic preparation is mixed with at least one encapsulated sunscreen prepared according to Claim 11 in such a proportion that the content of encapsulated sunscreen in the toiletry preparation is 0.1 to 10% by weight.
15. An encapsulated cosmetic, chemical, biological or pharmaceutical active material composition, characterised in that the encapsulated composition comprises microcapsules of a lipophilic cosmetic, chemical, biological or pharmaceutical active material composition encapsulated within a shell of the emulsion polymerisation product of a tetraalkoxysilane.
16. An encapsulated cosmetic, chemical, biological or pharmaceutical active material composition according to Claim 15, characterised in that the encapsulated composition is produced by the process of any of Claims 1 to 11,
17. An encapsulated cosmetic, chemical, biological or pharmaceutical active material composition according to Claim 15 or Claim 16, characterised in that the mean particle size of the microcapsules is between 200 nm and 10 μ m.

INTERNATIONAL SEARCH REPORT

Intern	Application No
PCT/EP 03/01071	

A. CLASSIFICATION OF SUBJECT MATTER		
IPC 7	B01J13/18	B01J13/20 A61K7/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7	B01J A61K
-------	-----------

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 199 54 772 A (REMMERS BAUCHEMIE GMBH) 17 May 2001 (2001-05-17) column 3, line 41 -column 4, line 29; claims 7,9; example 4	1,3,5-7, 15-17
A	US 4 169 069 A (UNGER KLAUS ET AL) 25 September 1979 (1979-09-25) the whole document	1-17
A	US 6 238 650 B1 (AVNIR DAVID ET AL) 29 May 2001 (2001-05-29) cited in the application the whole document	1-17

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the International search

Date of mailing of the International search report

2 June 2003

11/06/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Willscher, C

INTERNATIONAL SEARCH REPORT

Intern. Application No.
PCT, 03/01071

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01 80823 A (AVNIR DAVID ;GANS ORIT (IL); LAPIDOT NOA (IL); MAGDASSI SHLOMO (IL) 1 November 2001 (2001-11-01) cited in the application the whole document	1-17

INTERNATIONAL SEARCH REPORT

Interns Application No
PCT/EP 03/01071

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
DE 19954772	A	17-05-2001	DE	19954772 A1		17-05-2001
US 4169069	A	25-09-1979	DE	2642032 A1	30-03-1978	
			CH	633975 A5	14-01-1983	
			ES	462424 A1	16-12-1978	
			FR	2364686 A1	14-04-1978	
			GB	1588137 A	15-04-1981	
			JP	1320547 C	29-05-1986	
			JP	53037799 A	07-04-1978	
			JP	60045223 B	08-10-1985	
			SE	436468 B	17-12-1984	
			SE	7710397 A	19-03-1978	
US 6238650	B1	29-05-2001	AU	4775500 A	18-12-2000	
			BR	0011592 A	05-03-2002	
			CA	2370364 A1	07-12-2000	
			EP	1181001 A2	27-02-2002	
			WO	0072806 A2	07-12-2000	
			JP	2003500428 T	07-01-2003	
			US	2002037261 A1	28-03-2002	
WO 0180823	A	01-11-2001	AU	5251301 A	07-11-2001	
			BR	0110600 A	15-04-2003	
			WO	0180823 A2	01-11-2001	
			US	2002064541 A1	30-05-2002	